Schering-Plough CEO applauded for turnaround

BusinessWeek adds to the praise that's been heaped around Schering-Plough CEO Fred Hassan. After giving shareholders a dose of realism in 2003 when he took over, Hassan has been steadily rebuilding the company and positioning it for the future. Through it all he's had to inspire demoralized workers as well as investors, and has been given a tremendous amount of credit for accomplishing the task. His new mission lies in inspiring the workers at Organon Biosciences, which is being acquired in a $14.6 billion takeover. Hassan gave himself seven years to complete the turnaround, but some analysts say he's done a fine job in less than that.

- read the article from BusinessWeek

ALSO: Schering-Plough's stock was up this morning on more praise from analysts while the FTC is asking for more information on the takeover. Company officials describe the request as routine. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.